SEPTInvestingStart Free

CLLS SCHEDULE 13D/A: Insider sale planned

Bpifrance Participations and affiliated entities

Filed with the SEC on · accession 0001104659-26-124483

CLLS filed a SCHEDULE 13D/A (schedule 13d/a) with the SEC on Nov 9, 2026. Bpifrance Participations and affiliated entities filed an amended Schedule 13D reporting that CDC Croissance sold Cellectis ordinary shares in open market transactions on September 15-17, 2026. The stock moved +4.7% by the first close after the filing.

Summary of the filing

Bpifrance Participations and affiliated entities filed an amended Schedule 13D reporting that CDC Croissance sold Cellectis ordinary shares in open market transactions on September 15-17, 2026. The reporting persons collectively beneficially own 5,873,247 ordinary shares representing 10.0% of the class based on voting rights.

For details, click here →

Key details

Ordinary shares sold on September 15, 2026EUR 284K
Weighted average sale price on September 15, 2026EUR 1
Ordinary shares sold on September 16, 2026EUR 71K
Weighted average sale price on September 16, 2026EUR 1
Ordinary shares sold on September 17, 2026EUR 95K
Ordinary shares beneficially owned by reporting persons$5.9M
Voting rights held by reporting persons$9.6M
IssuerCellectis S.A.
Reporting person / 10% beneficial ownerBpifrance Participations SA
Reporting personCaisse des Depots
Reporting person / sellerCDC Croissance S.A.
Reporting personEPIC Bpifrance
Reporting personBpifrance S.A.

How CLLS stock reacted

Close before

$1.07

Nov 6, 2026

First close after

+4.67%

$1.12

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for CLLS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for CLLS?

Click here

Frequently asked questions

What did CLLS file with the SEC on Nov 9, 2026?

CLLS filed a SCHEDULE 13D/A (Insider sale planned). Bpifrance Participations and affiliated entities filed an amended Schedule 13D reporting that CDC Croissance sold Cellectis ordinary shares in open market transactions on September 15-17, 2026. The reporting persons collectively beneficially own 5,873,247 ordinary shares representing 10.0% of the class based on voting rights.

How do I read a SCHEDULE 13D/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D/A (schedule 13d/a): A report the company filed with the SEC (the US market regulator).

How did CLLS stock react to this filing?

CLLS closed at $1.07 before the filing and $1.12 on Nov 9, 2026 (+4.67%).

Other CLLS SEC filings

Get alerts when CLLS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
CLLS overviewCLLS analysisCLLS newsLatest SEC filings